DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
DIS3 gene mutations occur in approximately 10% of patients with multiple myeloma (MM); furthermore, DIS3 expression can be affected by monosomy 13 and del(13q), found in roughly 40% of MM cases. Despite the high incidence of DIS3 mutations and deletions, the biological significance of DIS3 and its contribution to MM pathogenesis remain poorly understood. In this study we investigated the functional role of DIS3 in MM, by exploiting a loss-of-function approach in human MM cell lines. We found that DIS3 knockdown inhibits proliferation in MM cell lines and largely affects cell cycle progression of MM plasma cells, ultimately inducing a significant increase in the percentage of cells in the G0/G1 phase and a decrease in the S and G2/M phases. DIS3 plays an important role not only in the control of the MM plasma cell cycle, but also in the centrosome duplication cycle, which are strictly co-regulated in physiological conditions in the G1 phase. Indeed, DIS3 silencing leads to the formation of supernumerary centrosomes accompanied by the assembly of multipolar spindles during mitosis. In MM, centrosome amplification is present in about a third of patients and may represent a mechanism leading to genomic instability. These findings strongly prompt further studies investigating the relevance of DIS3 in the centrosome duplication process. Indeed, a combination of DIS3 defects and deficient spindle-assembly checkpoint can allow cells to progress through the cell cycle without proper chromosome segregation, generating aneuploid cells which ultimately lead to the development of MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At the same time, exosome depletion or broader dysfunctions in nuclear RNA 3’ end processing4,48–56 often exhibit mutagenic potential in various models.”
From DIS3 mutations enhance AID-driven translocations during B-cell activation, promoting transformation to multiple myeloma (2026) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms3997 · Cited by 875
Self-citationWasmuth, E. V., & Lima, C. D. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.07.012 · Cited by 114 · cited 1×
“16,17 Moreover, studies in Schizosaccharomyces pombe have revealed functions of DIS3 in chromosome segregation, 18,19 cell cycle progression, 20,21 and spindle assembly.”
BackgroundRobinson, S., Oliver, A., Chevassut, T., & Newbury, S. (2015) · Biomolecules · doi:10.3390/biom5031515 · Cited by 71
Research works printed but not linked: 41
- Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013; 19(13):3337-3344. · DOI · Paper page
- Todoerti K, Ronchetti D, Favasuli V. DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. Haematologica. 2022; 107(4):921-932. · DOI · Paper page
- Lionetti M, Barbieri M, Todoerti K. A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Oncotarget. 2015; 6(28):26129-26141. · DOI · Paper page
- Boyle EM, Ashby C, Tytarenko RG. BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma. Clin Cancer Res. 2020; 26(10):2422-2432. · DOI · Paper page
- de Groen FLM, Krijgsman O, Tijssen M. Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression. Genes Chromosomes Cancer. 2014; 53(4):339-348. · DOI · Paper page
- Weißbach S, Langer C, Puppe B. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol. 2015; 169(1):57-70. · DOI · Paper page
- Ng D, Toure O, Wei MH. Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. Blood. 2007; 109(3):916-925. · DOI
- Rose AE, Poliseno L, Wang J. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res. 2011; 71(7):2561-2571. · DOI
- Binder M, Rajkumar SV, Ketterling RP. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017; 7(9):e600. · DOI
- Chiecchio L, Dagrada GP, Ibrahim AH. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica. 2009; 94(12):1708-1713. · DOI
- Tomecki R, Kristiansen MS, Lykke-Andersen S. The human core exosome interacts with differentially localized processive RNases: hDIS3 and hDIS3L. EMBO J. 2010; 29(14):2342-2357. · DOI · Paper page
- Schneider C, Leung E, Brown J, Tollervey D. The N-terminal PIN domain of the exosome subunit Rrp44 harbors endonuclease activity and tethers Rrp44 to the yeast core exosome. Nucleic Acids Res. 2009; 37(4):1127-1140. · DOI · Paper page
- Tomecki R, Drazkowska K, Kucinski I. Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target. Nucleic Acids Res. 2014; 42(2):1270-1290. · DOI · Paper page
- Mitchell P, Petfalski E, Shevchenko A, Mann M, Tollervey D. The exosome: a conserved eukaryotic RNA processing complex containing multiple 3′→5′ exoribonucleases. Cell. 1997; 91(4):457-466. · DOI · Paper page
- Kinoshita N, Goebl M, Yanagida M. The fission yeast dis3+ gene encodes a 110-kDa essential protein implicated in mitotic control. Mol Cell Biol. 1991; 11(12):5839-5847. · doi:10.1128/mcb.11.12.5839-5847.1991
- Ohkura H, Adachi Y, Kinoshita N, Niwa O, Toda T, Yanagida M. Coldsensitive and caffeine-supersensitive mutants of the Schizosaccharomyces pombe dis genes implicated in sister chromatid separation during mitosis. EMBO J. 1988; 7(5):1465-1473. · DOI · Paper page
- Noguchi E, Hayashi N, Azuma Y. Dis3, implicated in mitotic control, binds directly to Ran and enhances the GEF activity of RCC1. EMBO J. 1996; 15(20):5595-5605. · DOI
- Smith SB, Kiss DL, Turk E, Tartakoff AM, Andrulis ED. Pronounced and extensive microtubule defects in a Saccharomyces cerevisiae DIS3 mutant. Yeast Chichester Engl. 2011; 28(11):755-769. · DOI
- Murakami H, Goto DB, Toda T. Ribonuclease activity of Dis3 is required for mitotic progression and provides a possible link between heterochromatin and kinetochore function. PloS One. 2007; 2(3):e317. · DOI · Paper page
- Hou D, Ruiz M, Andrulis ED. The ribonuclease Dis3 is an essential regulator of the developmental transcriptome. BMC Genomics. 2012; 13:359. · DOI · Paper page
- Szczepińska T, Kalisiak K, Tomecki R. DIS3 shapes the RNA polymerase II transcriptome in humans by degrading a variety of unwanted transcripts. Genome Res. 2015; 25(11):1622-1633. · DOI · Paper page
- Gritti I, Basso V, Rinchai D. Loss of ribonuclease DIS3 hampers genome integrity in myeloma by disrupting DNA:RNA hybrid metabolism. EMBO J. 2022; 41(22) · DOI · Paper page
- Taiana E, Favasuli V, Ronchetti D. Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers antitumor activity in multiple myeloma. Leukemia. 2020; 34(1):234-244. · DOI
- Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022; 23(1):74-88. · DOI · Paper page
- Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol. 2007; 8(5):379-393. · DOI · Paper page
- Bruno S, Ghelli Luserna di Rorà A, Napolitano R, Soverini S, Martinelli G, Simonetti G. CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies. J Exp Clin Cancer Res CR. 2022; 41(1):159. · DOI
- Lub S, Maes A, Maes K. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget. 2016; 7(4):4062-4076. · DOI
- Pesenti ME, Raisch T, Conti D. Structure of the human inner kinetochore CCAN complex and its significance for human centromere organization. Mol Cell. 2022; 82(11):2113-2131. · DOI · Paper page
- Bolli N, Biancon G, Moarii M. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018; 32(12):2604-2616. · DOI · Paper page
- Santos-Pereira JM, Aguilera A. R loops: new modulators of genome dynamics and function. Nat Rev Genet. 2015; 16(10):583-597. · DOI · Paper page
- Nascakova Z, Boleslavska B, Urban V. RAD51 inhibition induces R-loop formation in early G1 phase of the cell cycle. Int J Mol Sci. 2021; 22(7):3740. · DOI
- Prigent C, Uzbekov R. Duplication and segregation of centrosomes during cell division. Cells. 2022; 11(15):2445. · DOI
- Lin M, Xie SS, Chan KY. An updated view on the centrosome as a cell cycle regulator. Cell Div. 2022; 17(1):1. · DOI
- Graham AC, Kiss DL, Andrulis ED. Core exosome-independent roles for Rrp6 in cell cycle progression. Mol Biol Cell. 2009; 20(8):2242-2253. · DOI
- Snee MJ, Wilson WC, Zhu Y. Collaborative control of cell cycle progression by the RNA exonuclease Dis3 and Ras is conserved across species. Genetics. 2016; 203(2):749-762. · DOI · Paper page
- Mittal K, Kaur J, Jaczko M. Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies. Cancer Metastasis Rev. 2021; 40(1):319-339. · DOI
- Krämer A, Neben K, Ho AD. Centrosome aberrations in hematological malignancies. Cell Biol Int. 2005; 29(5):375-383. · DOI
- Chng WJ, Fonseca R. Centrosomes and myeloma; aneuploidy and proliferation. Environ Mol Mutagen. 2009; 50(8):697-707. · DOI
- Dementyeva E, Kryukov F, Kubiczkova L. Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. J Transl Med. 2013; 11:77. · doi:10.1186/1479-5876-11-77
- Kryukova E, Kryukov F, Hajek R. Centrosome amplification and clonal evolution in multiple myeloma: short review. Crit Rev Oncol Hematol. 2016; 98:116-121. · DOI
- Díaz-Rodríguez E, Álvarez-Fernández S, Chen X. Deficient spindle assembly checkpoint in multiple myeloma. PloS One. 2011; 6(11):e27583. · DOI
Cited by
Kuliński, T. M., Gewartowska, O., Mahé, M., Kasztelan, K., Durys, N., Stroynowska-Czerwińska, A., Jedynak-Slyvka, M., Owczarek, E. P., Chaudhury, D., Nowotny, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70386-3 · Cited by 7
Metadata
- Authors
- Favasuli, V. K., Ronchetti, D., Silvestris, I., Puccio, N., Fabbiano, G., Traini, V., Todoerti, K., Erratico, S., Ciarrocchi, A., Fragliasso, V., Giannandrea, D., Tumiatti, F., Chiaramonte, R., Torrente, Y., Finelli, P., Morelli, E., Munshi, N. C., Bolli, N., Neri, A., & Taìana, E.
- Venue
- Haematologica
- Published
- 2023-07-13
- Volume
- 109
- Issue
- 1
- Pages
- 231-244
- ISSN
- 1592-8721
- 0390-6078
- Cited by
- 11
- References
- 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification. https://app.cochat.ai/papers/10.3324/haematol.2023.283274
- The paper
- Favasuli, V. K., Ronchetti, D., Silvestris, I., Puccio, N., Fabbiano, G., Traini, V., Todoerti, K., Erratico, S., Ciarrocchi, A., Fragliasso, V., Giannandrea, D., Tumiatti, F., Chiaramonte, R., Torrente, Y., Finelli, P., Morelli, E., Munshi, N. C., Bolli, N., Neri, A., & Taìana, E. (2023). DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification. Haematologica. https://doi.org/10.3324/haematol.2023.283274
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.